Dr. Reddy’s Laboratories Ltd. Feb. 2 said that the FDA has approved Zembrace SymTouch (sumatriptan succinate) injection, a drug-device combination product, for treating certain acute migraine episodes.
The company said Zembrace SymTouch is approved by the Food and Drug Administration for treating acute migraine episodes, with or without aura, in adults who are inadequately managed with existing migraine regimens.
The product is available as a pre-filled, single-dose disposable autoinjector containing 3 milligrams of sumatriptan, the company said. The injection is intended to be given subcutaneously.
“We are pleased to have received FDA approval for Zembrace SymTouch,” Raghav Chari, executive vice ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.